Tuyen Bui

1.7k total citations
35 papers, 1.2k citations indexed

About

Tuyen Bui is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Tuyen Bui has authored 35 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 16 papers in Molecular Biology and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Tuyen Bui's work include Cancer-related Molecular Pathways (22 papers), Advanced Breast Cancer Therapies (12 papers) and Microtubule and mitosis dynamics (9 papers). Tuyen Bui is often cited by papers focused on Cancer-related Molecular Pathways (22 papers), Advanced Breast Cancer Therapies (12 papers) and Microtubule and mitosis dynamics (9 papers). Tuyen Bui collaborates with scholars based in United States, France and South Korea. Tuyen Bui's co-authors include Khandan Keyomarsi, Kelly K. Hunt, Cansu Karakaş, Smruthi Vijayaraghavan, Saïd Akli, Min Yi, Yi Zhou, Lisa D. Auckland, Jason P.W. Carey and Xian Chen and has published in prestigious journals such as Nature Communications, Cancer Research and Oncogene.

In The Last Decade

Tuyen Bui

35 papers receiving 1.2k citations

Peers

Tuyen Bui

ONCOL

PRM

Nozomi Tomimatsu United States

Jennifer A. Perry United States

Lőrinc Sándor Pongor United States

Junko Odajima United States

Wenjian Gan United States

Laufey T. Ámundadóttir United States

Cédric Barrière France

Barbie Taylor‐Harding United States

Andrea Krempler Germany

Louise Aagaard Austria

Nozomi Tomimatsu United States

Tuyen Bui

616 ×0.9

ONCOL

1.3k ×2.2

178 ×0.5

PRM

312 ×1.4

142 ×0.8

Citations per year, relative to Tuyen Bui Tuyen Bui (= 1×) peers Nozomi Tomimatsu

Countries citing papers authored by Tuyen Bui

Since Specialization

Citations

This map shows the geographic impact of Tuyen Bui's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tuyen Bui with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tuyen Bui more than expected).

Fields of papers citing papers by Tuyen Bui

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tuyen Bui. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tuyen Bui. The network helps show where Tuyen Bui may publish in the future.

Co-authorship network of co-authors of Tuyen Bui

This figure shows the co-authorship network connecting the top 25 collaborators of Tuyen Bui. A scholar is included among the top collaborators of Tuyen Bui based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tuyen Bui. Tuyen Bui is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Luo, Linjie, Juliana Navarro-Yepes, Tuyen Bui, et al.. (2024). Abstract PO1-18-05: Combination treatment with CDK2 inhibitor (BLU-222) and either palbociclib or ribociclib is synergistic in pre-clinical models of CDK4/6 inhibitor-resistant breast cancer. Cancer Research. 84(9_Supplement). PO1–18. 1 indexed citations

Li, Mi, Amriti R. Lulla, Spyros Tsavachidis, et al.. (2024). Low–Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer. Cancer Research. 84(22). 3864–3880. 4 indexed citations

Navarro-Yepes, Juliana, Nicole M. Kettner, Xiayu Rao, et al.. (2023). Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast Cancers. Cancer Research. 83(19). 3264–3283. 24 indexed citations

Nguyen, Tuyen Duong Thanh, Tuyen Bui, Rossana Lazcano, et al.. (2023). Sequential Targeting of Retinoblastoma and DNA Synthesis Pathways Is a Therapeutic Strategy for Sarcomas That Can Be Monitored in Real Time. Cancer Research. 83(6). 939–955. 3 indexed citations

Chen, Xian, Angela Alexander, Yufeng Jiang, et al.. (2018). Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition. Clinical Cancer Research. 24(24). 6594–6610. 78 indexed citations

Carey, Jason P.W., Cansu Karakaş, Tuyen Bui, et al.. (2017). Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer. Cancer Research. 78(3). 742–757. 103 indexed citations

Francis, Ashleigh M., Angela Alexander, Yanna Liu, et al.. (2017). CDK4/6 Inhibitors Sensitize Rb-positive Sarcoma Cells to Wee1 Kinase Inhibition through Reversible Cell-Cycle Arrest. Molecular Cancer Therapeutics. 16(9). 1751–1764. 41 indexed citations

Doostan, Iman, Cansu Karakaş, Tuyen Bui, et al.. (2016). Cyclin E Associates with the Lipogenic Enzyme ATP-Citrate Lyase to Enable Malignant Growth of Breast Cancer Cells. Cancer Research. 76(8). 2406–2418. 75 indexed citations

Balaji, Kavitha, Smruthi Vijayaraghavan, Lixia Diao, et al.. (2016). AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers. Molecular Cancer Research. 15(1). 45–58. 70 indexed citations

10.

Chen, Xian, Tuyen Bui, Yufeng Jiang, et al.. (2016). Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer. Molecular Cancer Therapeutics. 15(4). 593–607. 51 indexed citations

11.

Karakaş, Cansu, Anna Biernacka, Tuyen Bui, et al.. (2016). Cytoplasmic Cyclin E and Phospho–Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast Cancer. American Journal Of Pathology. 186(7). 1900–1912. 48 indexed citations

12.

Bui, Tuyen, Cansu Karakaş, Jason P.W. Carey, et al.. (2015). PKCiota promotes ovarian tumor progression through deregulation of cyclin E. Oncogene. 35(19). 2428–2440. 17 indexed citations

13.

Bui, Tuyen, et al.. (2013). EVI1 splice variants modulate functional responses in ovarian cancer cells. Molecular Oncology. 7(3). 647–668. 32 indexed citations

14.

Bui, Tuyen, Michelle I. Smith, Rozita Bagheri‐Yarmand, et al.. (2013). Staurosporine is chemoprotective by inducing G 1 arrest in a Chk1- and pRb-dependent manner. Carcinogenesis. 34(10). 2244–2252. 8 indexed citations

15.

Akli, Saïd, Tuyen Bui, Hannah F. Wingate, et al.. (2010). Low-Molecular-Weight Cyclin E Can Bypass Letrozole-Induced G1 Arrest in Human Breast Cancer Cells and Tumors. Clinical Cancer Research. 16(4). 1179–1190. 41 indexed citations

16.

Bagheri‐Yarmand, Rozita, et al.. (2010). Cyclin E Deregulation Impairs Mitotic Progression through Premature Activation of Cdc25C. Cancer Research. 70(12). 5085–5095. 31 indexed citations

17.

Keyomarsi, Khandan, Ekem T. Efuet, & Tuyen Bui. (2010). Semi-high throughput method of measuring proteasome inhibition in vitro and in cultured cells. Cell Biology and Toxicology. 27(2). 123–131. 4 indexed citations

18.

Mull, Benjamin B., John V. Cox, Tuyen Bui, & Khandan Keyomarsi. (2009). Post-translational modification and stability of low molecular weight cyclin E. Oncogene. 28(35). 3167–3176. 10 indexed citations

19.

Wingate, Hannah F., Ágnes Puskás, MyLinh Duong, et al.. (2009). Low molecular weight cyclin E is specific in breast cancer and is associated with mechanisms of tumor progression. Cell Cycle. 8(7). 1062–1068. 40 indexed citations

20.

Akli, Saïd, Carolyn S. Van Pelt, Tuyen Bui, et al.. (2007). Overexpression of the Low Molecular Weight Cyclin E in Transgenic Mice Induces Metastatic Mammary Carcinomas through the Disruption of the ARF-p53 Pathway. Cancer Research. 67(15). 7212–7222. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact